US 12,110,322 B2
Anti-NGF antibodies and uses thereof
William Brondyk, Boston, MA (US); Jordan Willis, Boston, MA (US); and Leila Sevigny, Boston, MA (US)
Assigned to INVETX, INC., Boston, MA (US)
Filed by INVETX, INC., Boston, MA (US)
Filed on Jul. 6, 2023, as Appl. No. 18/348,173.
Application 18/348,173 is a continuation of application No. PCT/US2022/080428, filed on Nov. 23, 2022.
Claims priority of provisional application 63/282,590, filed on Nov. 23, 2021.
Claims priority of provisional application 63/383,173, filed on Nov. 10, 2022.
Prior Publication US 2024/0010717 A1, Jan. 11, 2024
Int. Cl. C07K 16/22 (2006.01)
CPC C07K 16/22 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01)] 30 Claims
 
1. An antigen binding protein that specifically binds to nerve growth factor (NGF), which comprises:
a heavy chain variable domain (VH) which comprises:
(a) a heavy chain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence X1X2X3X4TX6X7S (SEQ ID NO:378), wherein X1 comprises A or G, X2 comprises L or M, X3 comprises E or S, X4 comprises F or L, X6 comprises S or T, and X7 comprises H, N, or S;
(b) a heavy chain complementarity determining region 2 (VH-CDR2) comprising the amino acid sequence IWSNX5GT (SEQ ID NO:379), wherein X5 comprises G or R; and
(c) a heavy chain complementarity determining region 3 (VH-CDR3) comprising the amino acid sequence AX2IYYYX7ADYLHX13 YX15DX17 (SEQ ID NO:154) comprises, wherein X2 comprises N, Q, or S, X7 comprises D or E, X13 comprises F or W, X15 comprises F, I, L, W, or Y, and X17 comprises F, I, L, or M; and
a light chain variable domain (VL) which comprises:
(a) a light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence X1GIX4NX6 (SEQ ID NO:380), wherein X1 comprises D or E, X4 comprises Q or S, X6 comprises G, N, S or T;
(b) a light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence ATX3 (SEQ ID NO:156), wherein X3 comprises D, E, N, Q, or S; and
(c) a light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence QQGX4X5X6PLT (SEQ ID NO:157), wherein X4 comprises F, H, or Y, X5 comprises K or Q, and X6 comprises F or W.